List of Tables
Table 1. Chronic Pulmonary Hypertension Drug Market Trends
Table 2. Chronic Pulmonary Hypertension Drug Market Drivers & Opportunity
Table 3. Chronic Pulmonary Hypertension Drug Market Challenges
Table 4. Chronic Pulmonary Hypertension Drug Market Restraints
Table 5. Global Chronic Pulmonary Hypertension Drug Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Chronic Pulmonary Hypertension Drug Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Chronic Pulmonary Hypertension Drug Product Type
Table 9. Key Companies Time to Begin Mass Production of Chronic Pulmonary Hypertension Drug
Table 10. Global Chronic Pulmonary Hypertension Drug Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Pulmonary Hypertension Drug as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Chronic Pulmonary Hypertension Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Chronic Pulmonary Hypertension Drug Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Chronic Pulmonary Hypertension Drug Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Chronic Pulmonary Hypertension Drug Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Chronic Pulmonary Hypertension Drug Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Chronic Pulmonary Hypertension Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Chronic Pulmonary Hypertension Drug Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Chronic Pulmonary Hypertension Drug Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Chronic Pulmonary Hypertension Drug Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Chronic Pulmonary Hypertension Drug Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Chronic Pulmonary Hypertension Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Chronic Pulmonary Hypertension Drug Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Chronic Pulmonary Hypertension Drug Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Chronic Pulmonary Hypertension Drug Sales Value by Region (2019-2024) & (%)
Table 27. Global Chronic Pulmonary Hypertension Drug Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Chronic Pulmonary Hypertension Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Chronic Pulmonary Hypertension Drug Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Chronic Pulmonary Hypertension Drug Sales Value, (2025-2030) & (US$ Million)
Table 31. Bayer Basic Information List
Table 32. Bayer Description and Business Overview
Table 33. Bayer Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 34. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Bayer (2019-2024)
Table 35. Bayer Recent Developments
Table 36. Attgeno Basic Information List
Table 37. Attgeno Description and Business Overview
Table 38. Attgeno Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 39. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Attgeno (2019-2024)
Table 40. Attgeno Recent Developments
Table 41. Cereno Scientific Basic Information List
Table 42. Cereno Scientific Description and Business Overview
Table 43. Cereno Scientific Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 44. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Cereno Scientific (2019-2024)
Table 45. Cereno Scientific Recent Developments
Table 46. Bial - Portela C S.A Basic Information List
Table 47. Bial - Portela C S.A Description and Business Overview
Table 48. Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 49. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Bial - Portela C S.A (2019-2024)
Table 50. Bial - Portela C S.A Recent Developments
Table 51. Liquidia Technologies Basic Information List
Table 52. Liquidia Technologies Description and Business Overview
Table 53. Liquidia Technologies Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 54. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Liquidia Technologies (2019-2024)
Table 55. Liquidia Technologies Recent Developments
Table 56. Bellerophon Therapeutics Basic Information List
Table 57. Bellerophon Therapeutics Description and Business Overview
Table 58. Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 59. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Bellerophon Therapeutics (2019-2024)
Table 60. Bellerophon Therapeutics Recent Developments
Table 61. AbbVie Therapeutics Basic Information List
Table 62. AbbVie Therapeutics Description and Business Overview
Table 63. AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 64. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of AbbVie Therapeutics (2019-2024)
Table 65. AbbVie Therapeutics Recent Developments
Table 66. Insmed Basic Information List
Table 67. Insmed Description and Business Overview
Table 68. Insmed Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 69. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Insmed (2019-2024)
Table 70. Insmed Recent Developments
Table 71. Altavant Sciences Basic Information List
Table 72. Altavant Sciences Description and Business Overview
Table 73. Altavant Sciences Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 74. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Altavant Sciences (2019-2024)
Table 75. Altavant Sciences Recent Developments
Table 76. Lupin Basic Information List
Table 77. Lupin Description and Business Overview
Table 78. Lupin Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 79. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Lupin (2019-2024)
Table 80. Lupin Recent Developments
Table 81. Sun Pharmaceutical Basic Information List
Table 82. Sun Pharmaceutical Description and Business Overview
Table 83. Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 84. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Sun Pharmaceutical (2019-2024)
Table 85. Sun Pharmaceutical Recent Developments
Table 86. Teva Basic Information List
Table 87. Teva Description and Business Overview
Table 88. Teva Chronic Pulmonary Hypertension Drug Products, Services and Solutions
Table 89. Revenue (US$ Million) in Chronic Pulmonary Hypertension Drug Business of Teva (2019-2024)
Table 90. Teva Recent Developments
Table 91. Key Raw Materials Lists
Table 92. Raw Materials Key Suppliers Lists
Table 93. Chronic Pulmonary Hypertension Drug Downstream Customers
Table 94. Chronic Pulmonary Hypertension Drug Distributors List
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
Table 98. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Chronic Pulmonary Hypertension Drug Product Picture
Figure 2. Global Chronic Pulmonary Hypertension Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Chronic Pulmonary Hypertension Drug Sales Value (2019-2030) & (US$ Million)
Figure 4. Chronic Pulmonary Hypertension Drug Report Years Considered
Figure 5. Global Chronic Pulmonary Hypertension Drug Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Chronic Pulmonary Hypertension Drug Revenue in 2023
Figure 7. Chronic Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Oral Picture
Figure 9. Intravenous/Subcutaneous Picture
Figure 10. Inhalational Picture
Figure 11. Global Chronic Pulmonary Hypertension Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global Chronic Pulmonary Hypertension Drug Sales Value Market Share by Type, 2023 & 2030
Figure 13. Product Picture of Hospital Pharmacy
Figure 14. Product Picture of Retail Pharmacy
Figure 15. Product Picture of Online Pharmacy
Figure 16. Global Chronic Pulmonary Hypertension Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 17. Global Chronic Pulmonary Hypertension Drug Sales Value Market Share by Application, 2023 & 2030
Figure 18. North America Chronic Pulmonary Hypertension Drug Sales Value (2019-2030) & (US$ Million)
Figure 19. North America Chronic Pulmonary Hypertension Drug Sales Value by Country (%), 2023 VS 2030
Figure 20. Europe Chronic Pulmonary Hypertension Drug Sales Value (2019-2030) & (US$ Million)
Figure 21. Europe Chronic Pulmonary Hypertension Drug Sales Value by Country (%), 2023 VS 2030
Figure 22. Asia Pacific Chronic Pulmonary Hypertension Drug Sales Value (2019-2030) & (US$ Million)
Figure 23. Asia Pacific Chronic Pulmonary Hypertension Drug Sales Value by Country (%), 2023 VS 2030
Figure 24. South America Chronic Pulmonary Hypertension Drug Sales Value (2019-2030) & (US$ Million)
Figure 25. South America Chronic Pulmonary Hypertension Drug Sales Value by Country (%), 2023 VS 2030
Figure 26. Middle East & Africa Chronic Pulmonary Hypertension Drug Sales Value (2019-2030) & (US$ Million)
Figure 27. Middle East & Africa Chronic Pulmonary Hypertension Drug Sales Value by Country (%), 2023 VS 2030
Figure 28. Key Countries/Regions Chronic Pulmonary Hypertension Drug Sales Value (%), (2019-2030)
Figure 29. United States Chronic Pulmonary Hypertension Drug Sales Value, (2019-2030) & (US$ Million)
Figure 30. United States Chronic Pulmonary Hypertension Drug Sales Value by Type (%), 2023 VS 2030
Figure 31. United States Chronic Pulmonary Hypertension Drug Sales Value by Application (%), 2023 VS 2030
Figure 32. Europe Chronic Pulmonary Hypertension Drug Sales Value, (2019-2030) & (US$ Million)
Figure 33. Europe Chronic Pulmonary Hypertension Drug Sales Value by Type (%), 2023 VS 2030
Figure 34. Europe Chronic Pulmonary Hypertension Drug Sales Value by Application (%), 2023 VS 2030
Figure 35. China Chronic Pulmonary Hypertension Drug Sales Value, (2019-2030) & (US$ Million)
Figure 36. China Chronic Pulmonary Hypertension Drug Sales Value by Type (%), 2023 VS 2030
Figure 37. China Chronic Pulmonary Hypertension Drug Sales Value by Application (%), 2023 VS 2030
Figure 38. Japan Chronic Pulmonary Hypertension Drug Sales Value, (2019-2030) & (US$ Million)
Figure 39. Japan Chronic Pulmonary Hypertension Drug Sales Value by Type (%), 2023 VS 2030
Figure 40. Japan Chronic Pulmonary Hypertension Drug Sales Value by Application (%), 2023 VS 2030
Figure 41. South Korea Chronic Pulmonary Hypertension Drug Sales Value, (2019-2030) & (US$ Million)
Figure 42. South Korea Chronic Pulmonary Hypertension Drug Sales Value by Type (%), 2023 VS 2030
Figure 43. South Korea Chronic Pulmonary Hypertension Drug Sales Value by Application (%), 2023 VS 2030
Figure 44. Southeast Asia Chronic Pulmonary Hypertension Drug Sales Value, (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Chronic Pulmonary Hypertension Drug Sales Value by Type (%), 2023 VS 2030
Figure 46. Southeast Asia Chronic Pulmonary Hypertension Drug Sales Value by Application (%), 2023 VS 2030
Figure 47. India Chronic Pulmonary Hypertension Drug Sales Value, (2019-2030) & (US$ Million)
Figure 48. India Chronic Pulmonary Hypertension Drug Sales Value by Type (%), 2023 VS 2030
Figure 49. India Chronic Pulmonary Hypertension Drug Sales Value by Application (%), 2023 VS 2030
Figure 50. Chronic Pulmonary Hypertension Drug Industrial Chain
Figure 51. Chronic Pulmonary Hypertension Drug Manufacturing Cost Structure
Figure 52. Channels of Distribution (Direct Sales, and Distribution)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
